candesartan/hctz, irbesartan, irbesartan/hctz, olmesartan, olmesartan/hctz, telmisartan, telmisartan/hctz, ... To date, Torrent Pharmaceuticals Limited has not received any reports of adverse events related to this recall. Anonymous delivery. USA TODAY. Update [6/26/2019] FDA is alerting patients and health care professionals to Macleods Pharmaceuticals’ voluntary recall of two lots of losartan potassium tablets (50mg strength) and 30 lots of losartan potassium/hydrochlorothiazide (HCTZ) combination tablets (12 lots of 50mg/12.5mg strength, three … In November, the FDA announced a voluntary recall of losartan potassium/hydrochlorothiazide, 100 mg/25 mg tablets in 1,000-count plastic bottles, NDC 0781-5207-10, Lot number JB8912, Exp. However, not all ARBs have been affected, and patients should continue to use their medication, the FDA says. Blood pressure drug recall: 32 lots of losartan recalled over small amounts of carcinogen. The recalled losartan and potassium/hydrochlorothiazide combination tablets contained small amounts of N-nitrosodiethylamine, or NDEA, according to a company notice posted to the Food and Drug Administration's website Wednesday. "Based on the available information, the risk of developing cancer in a few patients following long-term use of the product cannot be ruled out," the recall notice states.The active drug ingredient was manufactured at Hetero Labs Limited in India, one of the overseas drug factories linked to repeated blood medication recalls since last July.Macleods also recalled one lot of the losartan combination drug in February for the same reason. Losartan is used to treat hypertension, hypertensive patients with Left Ventricular Hypertrophy and for the treatment of nephropathy in Type 2 diabetic patients. Background: Losartan, the first of the angiotensin II receptor blockers (ARBs) to be introduced, has been studied extensively in comparison with other classes of antihypertensive agents. UPDATE - Macleods Pharmaceuticals voluntarily recalls losartan containing NMBA. You can find Hydrochlorothiazide for the best price. BO31C016 and 4DK3C005 of Losartan Potassium USP tablets. NMBA is a "potential human carcinogen," the FDA says. For questions about returning the product, contact Qualanex via email at or call 888-280-2046 from 7 a.m. to 4 p.m. CST weekdays.Here are the doses, lot numbers and expiration dates of the recalled medicine: "The risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment," federal health officials wrote in a statement.The FDA has said the contaminants likely resulted from a manufacturing change adopted by factories in China and India that make the drug ingredients. Introduction: Losartan is the longest used angiotensin II receptor blocker in clinical practice. A recall of common blood pressure medication losartan has been expanded for a fifth time after manufacturer Torrent Pharmaceuticals found a possibly carcinogenic impurity in more batches of the drug, federal health officials said.Three additional lots of losartan potassium tablets and two additional lots of losartan potassium/hydrochlorothiazide tablets were under recall, the U.S. Food and Drug Administration said Thursday.The lots contained levels of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) above the acceptable daily intake levels determined by the FDA. The recall comes amid a larger string of recalls of blood pressure medications valsartan, losartan and irbesartan that contain trace levels of carcinogens NMBA, N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA), the FDA says.Hundreds of lots of the medication have been recalled since last July.The drugs, angiotensin II receptor blockers (ARBs), work by widening or relaxing blood vessels, thus lowering blood pressure. "Health care professionals advise patients to consult with their doctors or pharmacists before discontinuing one of the recalled blood pressure medicines or finding an alternative treatment.Discontinuing a recalled drug could cause more immediate harm than staying on the medication.Consumers with medical questions or to report an adverse event can contact Macleods at 855-926-3384 from 8 a.m. to 5 p.m. EST. Wide choice of products. December’s original recall covered lot Nos. The company said in the statement that for this recall "it has not received any reports of adverse effects. FDA scientists concluded there would be one more cancer case above average rates for every 8,000 people on the highest dose of valsartan for four years. Kelly Tyko. Less research has been conducted on the efficacy and tolerability of losartan compared with that of other ARBs. The manufacturing change may generate the contaminants "when specific chemicals and reaction conditions are present" and can result of reusing materials such as solvents.In January, the agency admitted that some versions of the drug valsartan contained trace amounts of a carcinogen for four years before regulators detected the impurity last summer.However, FDA officials said the cancer risk for any person who took valsartan that had the carcinogen N-nitrosodimethylamine, or NDMA, is small.

This expansion adds: This expansion adds: … A recall of common blood pressure medication losartan has been expanded for a fifth time after manufacturer Torrent Pharmaceuticals found a possibly carcinogenic impurity in … Low prices.